PharmaCorp Rx Inc. (TSXV:PCRX)

Canada flag Canada · Delayed Price · Currency is CAD
0.5000
-0.0100 (-1.96%)
At close: Jul 10, 2026
Market Cap87.04M +51.0%
Revenue (ttm)24.08M +145.6%
Net Income-1.62M
EPS-0.01
Shares Out 174.08M
PE Ration/a
Forward PE25.00
Dividendn/a
Ex-Dividend Daten/a
Volume197,256
Open0.5100
Previous Close0.5100
Day's Range0.5000 - 0.5100
52-Week Range0.4000 - 0.5800
Beta-4.27
AnalystsStrong Buy
Price Target0.67 (+34.0%)
Earnings DateAug 14, 2026

About PharmaCorp Rx

PharmaCorp Rx Inc. operates retail pharmacies under the PharmaChoice name in Canada. The company offers prescription services; front-of-store retail, such as convenience goods, over-the-counter medications, health products, and wellness items; custom compounding; specialized consultations; and lifestyle programs. PharmaCorp Rx Inc. was incorporated in 2021 and is headquartered in Saskatoon, Canada. [Read more]

Sector Healthcare
Founded 2021
Employees 5
Stock Exchange TSX Venture Exchange
Ticker Symbol PCRX
Full Company Profile

Financial Performance

In 2025, PharmaCorp Rx's revenue was 20.89 million, an increase of 260.57% compared to the previous year's 5.79 million. Losses were -1.48 million, 46.3% more than in 2024.

Financial Statements

Analyst Summary

According to 3 analysts, the average rating for PCRX stock is "Strong Buy." The 12-month stock price target is $0.67, which is an increase of 34.00% from the latest price.

Price Target
$0.67
(34.00% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

PharmaCorp Rx Slides: Investor presentation

PharmaCorp Rx has posted slides in relation to its latest quarterly earnings report, which was published on June 9, 2026.

4 weeks ago - Filings

PharmaCorp Rx Registration statement: Q1 2026

PharmaCorp Rx filed a registration statement on June 1, 2026, providing details about a securities offering with the SEC.

5 weeks ago - Filings

PharmaCorp Rx Registration statement: Q1 2026

PharmaCorp Rx filed a registration statement on June 1, 2026, providing details about a securities offering with the SEC.

5 weeks ago - Filings

PharmaCorp Rx Earnings release: Q1 2026

PharmaCorp Rx released its Q1 2026 earnings on June 1, 2026, summarizing the period's financial results.

5 weeks ago - Filings

PharmaCorp Rx Slides: Investor presentation

PharmaCorp Rx has posted slides in relation to its latest quarterly earnings report, which was published on May 6, 2026.

2 months ago - Filings

PharmaCorp Rx Earnings release: Q4 2025

PharmaCorp Rx released its Q4 2025 earnings on April 29, 2026, summarizing the period's financial results.

2 months ago - Filings

PharmaCorp Rx Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference

At the 2026 Bloom Burton Healthcare Investor Conference, a pharmacy roll-up firm detailed its exclusive acquisition pipeline, flexible exit options for owners, and focus on operational stability and top-line growth. Recent capital raised will fund further expansion and team growth.

2 months ago - Transcripts

PharmaCorp Rx Earnings release: Q3 2025

PharmaCorp Rx released its Q3 2025 earnings on November 27, 2025, summarizing the period's financial results.

8 months ago - Filings

PharmaCorp Rx Slides: Q3 2025

PharmaCorp Rx has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 27, 2025.

8 months ago - Filings

PharmaCorp Rx Earnings release: Q2 2025

PharmaCorp Rx released its Q2 2025 earnings on August 15, 2025, summarizing the period's financial results.

11 months ago - Filings

PharmaCorp Rx Slides: Q2 2025

PharmaCorp Rx has posted slides in relation to its Q2 2025 quarterly earnings report, which was published on August 15, 2025.

11 months ago - Filings